Anderman Jonathan
Transaction: 04/29/2026
BUY
Change
+25,000
Price
$1.89
Filing
04/30/2026
Type
BUY
Compass Therapeutics, Inc.
CMPX • Biotechnology
$2.38
▲ +0.01 (+0.42%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$444.58M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.05Healthy liquidity · 15.02Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 12, 2026, 12:49 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$2.38
Change0.42%
Shares Out186.80M
Market Cap$444.58M
Enterprise Value$274.33M
52W Range1.61 - 6.88
Beta0.82
P/E-6.05
P/B2.68
P/FCF-8.08
EV/EBITDA-3.57
EV/FCF-4.98
Price$2.38
Change0.42%
Shares Out186.80M
Market Cap$444.58M
Enterprise Value$274.33M
52W Range1.61 - 6.88
Beta0.82
P/E-6.05
P/B2.68
P/FCF-8.08
EV/EBITDA-3.57
EV/FCF-4.98
Earnings Yield-16.52%
FCF Yield-12.38%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.05
Current Ratio15.02
Quick Ratio15.02
Target$7.50
Target Upside215.13%
Target Median$7.50
Target Range6.00 - 9.00
Volume3.97M
Avg Volume7.58M
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
43
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
67/100
Why this score▼
Manageable debt level · 0.05Healthy liquidity · 15.02Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 16 analyst votes · 2026-09-05
100/100
Bullish
Bullish
16
Hold
0
Bearish
0
Price Target
2026-08-12
Low
$6.00
Mean
$10.00
Median
$9.00
High
$15.00
Insider Transactions
Recent executive and insider activity
Lerner Neil
Transaction: 04/29/2026
BUY
Change
+15,000
Price
$1.89
Filing
04/30/2026
Type
BUY
Lerner Neil
Transaction: 04/29/2026
BUY
Change
+15,000
Price
$1.89
Filing
04/29/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Anderman Jonathan | BUY | +25,000 | $1.89 | 04/29/2026 | 04/30/2026 |
| Lerner Neil | BUY | +15,000 | $1.89 | 04/29/2026 | 04/30/2026 |
| Lerner Neil | BUY | +15,000 | $1.89 | 04/29/2026 | 04/29/2026 |
| Anderman Jonathan | BUY | +25,000 | $1.89 | 04/29/2026 | 04/29/2026 |
| Schuetz Thomas J. | SELL | -36,687 | $6.52 | 02/08/2026 | 02/10/2026 |
| Schuetz Thomas J. | SELL | -46,777 | $5.35 | 01/09/2026 | 01/12/2026 |
| Prasad Arjun | OTHER | 0 | Not reported | 01/02/2026 | 01/05/2026 |
| Sirard Cynthia | OTHER | 0 | Not reported | 01/02/2026 | 01/05/2026 |
| Anderman Jonathan | BUY | +150,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| Anderman Jonathan | BUY | +720,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| Ferneau Philip | BUY | +90,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| GORDON CARL L | BUY | +90,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| Boylan James P | BUY | +90,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| GRAY MARY ANN | BUY | +90,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| Lerner Neil | BUY | +62,500 | $5.17 | 01/02/2026 | 01/05/2026 |
| Lerner Neil | BUY | +435,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| Chiniara Ellen | BUY | +90,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| LINDAHL RICHARD S | BUY | +90,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| Prasad Arjun | BUY | +1,000,000 | $5.17 | 01/02/2026 | 01/05/2026 |
| Schuetz Thomas J. | BUY | +2,000,000 | $5.17 | 01/02/2026 | 01/05/2026 |